CRISPR and the cancer link. Who said what?

41124064215_2984b6abeb_h

Credit: Ernesto del Aguila III, National Human Genome Research Institute, NIH

A pair of papers published in Nature Medicine have caused a stir about CRISPR-edited cells lacking a well-known tumor suppressor gene. STAT is doing an online chat next week to follow up the news. In the meantime, this is a sample of how the CRISPR community is commenting the story. Continue reading

From antisense to CRISPR. Q&A with Ed Wild

ed wild

Dr Ed Wild at the Vatican with co-discoverer of the HD gene – Nancy Wexler

Ed Wild of University College London is a leading scientist and the international coordinator (with Sarah Tabrizi) in a very promising trial using antisense oligonucleotide technology in Huntington patients. This is the interview he gave me before attending the Huntington’s Days 2018 meeting in Turin, Italy.  Continue reading

CRISPR futures. Q&A with Jennifer Doudna

Doudna, Jennifer

Credit: Keegan Houser/UC Berkeley

Interview given to Anna Meldolesi (Corriere della sera, 15 May 2018)

The CRISPR biomedical duel between China and the US has been called “Sputnik 2.0”. Is Europe being left behind?

JD: As with any disruptive technology, there is intense competition to lead. However, unlike the space race, the CRISPR research effort is global and more collaborative. We consistently see key advances in CRISPR technology shared through scientific papers, written and read by research teams around the world. This collective approach has helped to democratize the technology. However, differing regulations across countries may impact how we ultimately translate research into real-world applications that can benefit the most number of people with the most need. Researchers in Europe have made valuable contributions to the development and application of CRISPR and will continue to play a role in establishing global standards. Continue reading

China vs USA: who leads the CRISPR race?

China vs US

The first human CRISPR trial approved in the United States is finally recruiting the first patient. In the meantime trials have grown to a dozen in China, considering those revealed by the Wall Street Journal inquiry besides the NIH database (check also this npr article for further details). Over 80 Chinese patients are already receiving a CRISPR-based treatment, while US researchers cautiously plan to test the safety of their experimental therapy on a single subject, and, if everything goes right, two more patients will be treated a month later. Is the West losing its genome-editing edge to Beijing? Continue reading

Playing a three of CRISPR kind

three acesIt is Science but it could be mistaken for The CRISPR Journal. The latest issue indeed runs three papers by three CRISPR aces – David Liu, Jennifer Doudna, and Feng Zhang – about the cutting-edge fields of biological recorders and advanced diagnostic tests. Continue reading

CRISPR latest edition

crispr-latest-edition[8047]There is hardly any day without CRISPR news. February starts with researchers correcting abnormalities associated with Duchenne muscular dystrophy (Science Advances) and performing allele-specific editing in blind mice (bioRxiv, forthcoming in The CRISPR Journal). A repechage from January also: how to get pluripotent stem cells by CRISPRing just one gene (Cell Stem Cell).